Phage therapy could be key to conquering persistent bacterial lung infections in children.

Persistent bacterial lung infections in children lead to significant morbidity and mortality due to antibiotic resistance. In this paper, we describe how phage therapy has shown remarkable efficacy in preclinical and clinical studies, demonstrating significant therapeutic benefits through various administration routes. Ongoing trials are evaluating its safety and effectiveness against different pathogens. Advancing phage therapy through systematic studies and international collaboration could provide a viable alternative to traditional antibiotics for persistent infections.
Competing Interests: Competing interests: A.M.S.S., P.H., A.K., P.P., K.M., L.C., K.S., M.A., P.M, A.Ki., T.C., P.G.H., and S.A. declare no financial or non-financial competing interests. D.L.W. serves as an editorial board member of this journal and had no role in the peer-review or decision to publish this manuscript. D.L.W. declares no financial competing interests.
(© 2024. The Author(s).)